PENETHAONE Powder and solvent for suspension for injection for cattle

Authorised

• Penethamate hydriodide

Product identification

Medicine name:

PENETHAONE Powder and solvent for suspension for injection for cattle Penethaone pro skot, 236.3mg/ml, Prášek a rozpouštědlo pro injekční suspenzi

Active substance:

Penethamate hydriodide

Target species:

Cattle (lactating cow)

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Penethamate hydriodide 236.30 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Powder and solvent for suspension for injection

Withdrawal period by route of administration: Intramuscular use:

- Cattle (lactating cow)
 - Meat and offal. 4 day
 - Milk. no withdrawal period Meat and offal: 4 days; Milk: 2,5 days/60 hours.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CE90

Legal status of supply:

This information is not available for this product.

Authorisation status:

Valid

Authorised in:

Czechia

Package description:

box containing $10 \times 10,000,000$ IU powder vial and 10×36 ml solvent vial box containing $5 \times 10,000,000$ IU powder vial and 5×36 ml solvent vial box containing $1 \times 10,000,000$ IU powder vial and 1×36 ml solvent vial box containing $10 \times 5,000,000$ IU powder vial and 10×18 ml solvent vial box containing $5 \times 5,000,000$ IU powder vial and 5×18 ml solvent vial box containing $1 \times 5,000,000$ IU powder vial and 1×18 ml solvent vial

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Divasa Farmavic S.A.

Marketing authorisation date:

7/06/2016

Manufacturing sites for batch release:

Divasa Farmavic S.A.

Responsible authority:

Institute For State Control Of Veterinary Biologicals And Medicaments

Authorisation number:

96/045/16-C

Date of authorisation status change:

7/06/2016

Reference member state:

Spain

Procedure number:

ES/V/0226/001

Concerned member states:

Austria Belgium Bulgaria Czechia Denmark France Germany Greece Hungary Iceland Ireland Italy Lithuania Netherlands Norway Poland Portugal Romania Slovakia Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 26/12/2023

Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Source URL: https://medicines.health.europa.eu/veterinary/600000083035